Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60081
Name triple-receptor negative breast cancer
Definition A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Rivoceranib triple-receptor negative breast cancer not applicable detail...
Unknown unknown AMG 900 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Alisertib + Docetaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Lucitanib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Evofosfamide triple-receptor negative breast cancer not applicable detail...
Unknown unknown Tirapazamine triple-receptor negative breast cancer not applicable detail...
Unknown unknown SN30000 triple-receptor negative breast cancer not applicable detail...
Unknown unknown PR-104 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BMS-906024 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Eribulin triple-receptor negative breast cancer not applicable detail...
NOTCH1 S2449fs PF-03084014 triple-receptor negative breast cancer sensitive detail...
NOTCH1 mutant PF-03084014 triple-receptor negative breast cancer sensitive detail...
Unknown unknown KW-2450 triple-receptor negative breast cancer not applicable detail...
Unknown unknown KW-2450 + Selumetinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Senexin B triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY1217389 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY1161909 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + NTRC 0066-0 triple-receptor negative breast cancer not applicable detail...
NOTCH1 rearrange MRK-003 triple-receptor negative breast cancer sensitive detail...
NOTCH1 rearrange MRK-003 + SCH772984 triple-receptor negative breast cancer no benefit detail...
NOTCH1 wild-type MRK-003 triple-receptor negative breast cancer decreased response detail...
NOTCH1 rearrange MRK-003 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
NOTCH1 wild-type MRK-003 + Paclitaxel triple-receptor negative breast cancer no benefit detail...
Unknown unknown TVB-2640 triple-receptor negative breast cancer not applicable detail...
Unknown unknown CCT007093 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown CCT007093 triple-receptor negative breast cancer no benefit detail...
Unknown unknown Paclitaxel + Plicamycin triple-receptor negative breast cancer not applicable detail...
Unknown unknown LY2109761 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown SKLB646 triple-receptor negative breast cancer not applicable detail...
PIK3CA mutant Palbociclib + Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA wild-type Palbociclib + Pictilisib triple-receptor negative breast cancer no benefit detail...
SRC positive KX2-391 triple-receptor negative breast cancer sensitive detail...
SRC positive KX2-391 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 over exp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 triple-receptor negative breast cancer sensitive detail...
Unknown unknown Alisertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
SRC positive UM-164 triple-receptor negative breast cancer predicted - sensitive detail...
SRC positive BIRB-796 + Dasatinib triple-receptor negative breast cancer sensitive detail...
Unknown unknown Pemetrexed Disodium + Sorafenib triple-receptor negative breast cancer not applicable detail...
Unknown unknown YLL545 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Foretinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bevacizumab + Capecitabine + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Birabresib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 + Vinorelbine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cisplatin + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carboplatin + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown AMG 900 + Ixabepilone triple-receptor negative breast cancer not applicable detail...
PIK3CA mutant Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA amp Linsitinib + Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA amp NVP-AEW541 + Pictilisib triple-receptor negative breast cancer sensitive detail...
Unknown unknown Selumetinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carboplatin + Docetaxel + Gemcitabine + Itraconazole triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY 11-7082 + Erlotinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Adavosertib + Everolimus triple-receptor negative breast cancer not applicable detail...
Unknown unknown YM155 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bortezomib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carfilzomib triple-receptor negative breast cancer not applicable detail...
Unknown unknown KP372-1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Crizotinib + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cabozantinib + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Navitoclax + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Nutlin-3a + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
PIK3CA act mut Bevacizumab + Doxorubicin + Everolimus triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA act mut Bevacizumab + Doxorubicin + Temsirolimus triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown BETd-246 + BM-1197 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BETd-246 + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown A-1155463 + BETd-246 triple-receptor negative breast cancer not applicable detail...
Unknown unknown SY-1365 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Niraparib + SY-1365 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BPM 31510 triple-receptor negative breast cancer not applicable detail...
Unknown unknown LY3200882 triple-receptor negative breast cancer not applicable detail...
Unknown unknown CFI-402257 triple-receptor negative breast cancer not applicable detail...
Unknown unknown PF-06647263 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Ipatasertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
PIK3CA mutant Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
AKT1 mutant Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown ONC201 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + ONC201 triple-receptor negative breast cancer not applicable detail...
Unknown unknown ONC201 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
AKT1 E17K Capivasertib triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown ASTX-660 triple-receptor negative breast cancer not applicable detail...
Unknown unknown ASTX-660 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown G-TPP + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown G-TPP + Obatoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cisplatin + Everolimus + Paclitaxel triple-receptor negative breast cancer no benefit detail...
Unknown unknown Carfilzomib + Tinostamustine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bortezomib + Tinostamustine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Capivasertib + Olaparib triple-receptor negative breast cancer not applicable detail...
Unknown unknown S63845 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + S63845 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cyclophosphamide + Doxorubicin + Elenagen triple-receptor negative breast cancer not applicable detail...
ERBB2 V697L Neratinib triple-receptor negative breast cancer sensitive detail...
FGFR2 - TNS1 Infigratinib triple-receptor negative breast cancer sensitive detail...
FGFR2 - TNS1 Buparlisib + Infigratinib triple-receptor negative breast cancer sensitive detail...
FGFR2 - TNS1 Buparlisib triple-receptor negative breast cancer no benefit detail...
Unknown unknown Triptolide triple-receptor negative breast cancer not applicable detail...
Unknown unknown Selumetinib + SHP099 triple-receptor negative breast cancer not applicable detail...
STK11 F354L Everolimus + Exemestane triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown AVID200 triple-receptor negative breast cancer not applicable detail...
Unknown unknown LTX-315 + Pegylated liposomal-doxorubicin triple-receptor negative breast cancer not applicable detail...
Unknown unknown CC-671 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Capivasertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown MIW815 + Spartalizumab triple-receptor negative breast cancer not applicable detail...
Unknown unknown SMI#9-GNP triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cisplatin + SR-4835 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Irinotecan + SR-4835 triple-receptor negative breast cancer not applicable detail...
Unknown unknown SR-4835 triple-receptor negative breast cancer not applicable detail...
Unknown unknown RhFzd7 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + RhFzd7 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Fluzoparib triple-receptor negative breast cancer not applicable detail...
Unknown unknown GSK3368715 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BOS172722 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BOS172722 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + DT2216 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Doxorubicin + DT2216 triple-receptor negative breast cancer not applicable detail...
Unknown unknown DT2216 + Vincristine Sulfate triple-receptor negative breast cancer not applicable detail...
Unknown unknown GSK2801 + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAZ2-ICR + BI-9564 + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAZ2-ICR + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Birabresib + GSK2801 triple-receptor negative breast cancer not applicable detail...
Unknown unknown GSK2801 + HY-16462 triple-receptor negative breast cancer no benefit detail...
Unknown unknown HY-16462 + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown CPI-637 + HY-16462 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Sacituzumab govitecan-hziy triple-receptor negative breast cancer not applicable detail...
Unknown unknown MGD013 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Alisertib + Sapanisertib triple-receptor negative breast cancer not applicable detail...
AKT1 E17K Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA act mut Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Olaparib + THZ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Enzalutamide + Taselisib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carboplatin + Gemcitabine + Trilaciclib triple-receptor negative breast cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed
NCT01562873 Phase II Ruxolitinib Ruxolitinib in Patients With Breast Cancer Terminated
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed
NCT01623349 Phase I Alpelisib + Olaparib Buparlisib + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Active, not recruiting
NCT01639248 Phase II ENMD-2076 Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Completed
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01931163 Phase II Everolimus NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Completed
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed
NCT01969643 Phase I Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab A Safety Study of SGN-LIV1A in Breast Cancer Patients Recruiting
NCT01982448 Phase II Paclitaxel Cisplatin Cisplatin vs Paclitaxel for Triple Neg Active, not recruiting
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Active, not recruiting
NCT01997333 Phase II Glembatumumab vedotin Capecitabine Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT02000882 Phase II Buparlisib + Capecitabine Capecitabine + BKM120 TNBC BC Brain Met Completed
NCT02003092 Phase I RX-5902 RX-5902 Treatment of Subjects With Solid Tumors Terminated
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) Active, not recruiting
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed
NCT02078752 Phase I PF-06647263 A Study Of PF-06647263 In Patients With Advanced Solid Tumors Terminated
NCT02101385 Phase II Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer Active, not recruiting
NCT02120469 Phase I Eribulin + Everolimus Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Active, not recruiting
NCT02138812 Phase I BAY1161909 + Paclitaxel Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Terminated
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed
NCT02158507 Phase I Lapatinib + Veliparib Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer Active, not recruiting
NCT02162719 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Completed
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Active, not recruiting
NCT02187991 Phase II Paclitaxel Alisertib + Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02276443 Phase 0 Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative Recruiting
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed
NCT02299635 Phase II PF-03084014 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed
NCT02322814 Phase II Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Active, not recruiting
NCT02358200 Phase I Carboplatin + Paclitaxel + Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Terminated
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02366949 Phase I BAY1217389 + Paclitaxel Paclitaxel Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Completed
NCT02368691 Phase II Enobosarm Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) Terminated
NCT02370238 Phase II Reparixin A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer Unknown status
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed
NCT02393794 Phase Ib/II Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Suspended
NCT02401347 Phase II Talazoparib Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors Recruiting
NCT02411656 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Recruiting
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Recruiting
NCT02425891 Phase III Atezolizumab + Nab-paclitaxel Nab-paclitaxel A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) Active, not recruiting
NCT02427581 Phase I Poly ICLC Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02435680 Phase II MCS110 Carboplatin + Gemcitabine Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) Completed
NCT02447003 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) Completed
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated
NCT02456857 Phase II Bevacizumab Everolimus Pegylated liposomal-doxorubicin Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative Recruiting
NCT02457910 Phase Ib/II Enzalutamide Enzalutamide + Taselisib Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed
NCT02474173 Phase I Paclitaxel Onalespib Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Active, not recruiting
NCT02489448 Phase Ib/II Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer Suspended
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting
NCT02513472 Phase Ib/II Eribulin + Pembrolizumab Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1) Active, not recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed
NCT02530489 Phase II Atezolizumab + Nab-paclitaxel Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer Recruiting
NCT02531932 Phase II Carboplatin Everolimus Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Active, not recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated
NCT02574455 Phase III Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) Active, not recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02580448 Phase Ib/II VT-464 A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed
NCT02593175 Phase II Carboplatin + Paclitaxel + Panitumumab Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Recruiting
NCT02624700 Phase II Pemetrexed Disodium + Sorafenib Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer Terminated
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting
NCT02637375 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02648477 Phase II Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) Active, not recruiting
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed
NCT02672475 Phase I Galunisertib + Paclitaxel Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Recruiting
NCT02676986 Phase II Enzalutamide + Exemestane Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Active, not recruiting
NCT02689427 Phase II Enzalutamide + Paclitaxel Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Recruiting
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Recruiting
NCT02708680 Phase Ib/II Atezolizumab Atezolizumab + Entinostat Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Active, not recruiting
NCT02719691 Phase I Alisertib + Sapanisertib Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer Recruiting
NCT02720185 Phase II Dasatinib Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Recruiting
NCT02730130 Phase II Pembrolizumab Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Active, not recruiting
NCT02734290 Phase Ib/II Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer Active, not recruiting
NCT02750358 Phase II Enzalutamide Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Active, not recruiting
NCT02752685 Phase II Nab-paclitaxel + Pembrolizumab Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Recruiting
NCT02755272 Phase II Pembrolizumab Carboplatin + Gemcitabine A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Active, not recruiting
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Active, not recruiting
NCT02768701 Phase II Cyclophosphamide + Pembrolizumab Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed
NCT02788981 Phase II Mifepristone + Nab-paclitaxel Nab-paclitaxel Abraxane With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Recruiting
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Active, not recruiting
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed
NCT02826434 Phase I Durvalumab + Poly ICLC + PVX-410 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Active, not recruiting
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated
NCT02834403 Phase Ib/II Pegfilgrastim Docetaxel + L-NMMA L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Recruiting
NCT02876107 Phase II Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Recruiting
NCT02876302 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed
NCT02883062 Phase II Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Active, not recruiting
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Recruiting
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Active, not recruiting
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Active, not recruiting
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting
NCT02929576 Phase III Paclitaxel Enzalutamide + Paclitaxel Enzalutamide Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) Withdrawn
NCT02936102 Phase I FAZ053 FAZ053 + Spartalizumab A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting
NCT02938442 Phase II Montanide ISA 51 + P10s-PADRE Vaccination of Triple Negative Breast Cancer Patients Recruiting
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Active, not recruiting
NCT02954874 Phase III Pembrolizumab Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Recruiting
NCT02971761 Phase II Enobosarm + Pembrolizumab Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT02977468 Phase I Pembrolizumab Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) Recruiting
NCT02978716 Phase II Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Active, not recruiting
NCT02981303 Phase II Pembrolizumab + PGG beta-glucan Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Active, not recruiting
NCT02984683 Phase II SAR566658 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer Completed
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Available
NCT02996825 Phase I Gemcitabine + Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting
NCT03012100 Phase II Cyclophosphamide + Sargramostim Cyclophosphamide + FR alpha peptide vaccine + Sargramostim Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Recruiting
NCT03012230 Phase I Pembrolizumab + Ruxolitinib Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer Recruiting
NCT03012477 Phase II Adavosertib + Cisplatin CISPLATIN + AZD-1775 In Breast Cancer Active, not recruiting
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03036488 Phase III Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status
NCT03090165 Phase Ib/II Bicalutamide + Ribociclib Ribociclib and Bicalutamide in AR+ TNBC Active, not recruiting
NCT03095352 Phase II Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Recruiting
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Active, not recruiting
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting
NCT03106077 Phase II Mirvetuximab Soravtansine Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) Completed
NCT03106415 Phase Ib/II Binimetinib + Pembrolizumab Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Suspended
NCT03121352 Phase I Carboplatin + Nab-paclitaxel + Pembrolizumab Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Active, not recruiting
NCT03125902 Phase III Paclitaxel Atezolizumab + Paclitaxel A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) Active, not recruiting
NCT03130439 Phase II Abemaciclib Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03167619 Phase II Durvalumab + Olaparib Olaparib Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) Recruiting
NCT03184558 Phase II Bemcentinib + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With TNBC Completed
NCT03193853 Phase II Cisplatin + Nab-paclitaxel MLN1117 + Sapanisertib TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer Recruiting
NCT03197935 Phase III Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) Active, not recruiting
NCT03199040 Phase I Durvalumab Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Recruiting
NCT03206203 Phase II Atezolizumab + Carboplatin Carboplatin Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer Recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03213041 Phase II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Recruiting
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03225547 Phase II Mifepristone + Pembrolizumab Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Recruiting
NCT03243331 Phase I Cofetuzumab pelidotin + Gedatolisib An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer Recruiting
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Active, not recruiting
NCT03281954 Phase III Atezolizumab Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Terminated
NCT03310957 Phase Ib/II Ladiratuzumab vedotin + Pembrolizumab Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer Recruiting
NCT03316586 Phase II Cabozantinib + Nivolumab A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Active, not recruiting
NCT03316794 Phase I SC-005 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Terminated
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting
NCT03330847 Phase II Adavosertib + Olaparib Olaparib AZD6738 + Olaparib To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Recruiting
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Recruiting
NCT03361800 Phase I Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Active, not recruiting
NCT03362060 Phase I Pembrolizumab + PVX-410 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Recruiting
NCT03363893 Phase Ib/II ICEC0942 Fulvestrant + ICEC0942 Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Recruiting
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Recruiting
NCT03371017 Phase III Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) Recruiting
NCT03387085 Phase Ib/II ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting
NCT03414684 Phase II Carboplatin + Nivolumab Carboplatin Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Recruiting
NCT03424005 Phase Ib/II Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03483012 Phase II Atezolizumab Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis Recruiting
NCT03487666 Phase II Capecitabine + Nivolumab Capecitabine Nivolumab OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Recruiting
NCT03498716 Phase III Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Paclitaxel A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) Recruiting
NCT03499899 Phase II Carboplatin + LAG525 Carboplatin + LAG525 + Spartalizumab LAG525 + Spartalizumab A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer Active, not recruiting
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03519178 Phase II PF-06873600 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03542175 Phase I Rucaparib A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Recruiting
NCT03544125 Phase I Durvalumab + Olaparib Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT03546686 Phase II Ipilimumab + Nivolumab Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer Recruiting
NCT03554109 Phase II Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Withdrawn
NCT03556228 Phase I VMD-928 Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma Recruiting
NCT03562637 Phase III Adagloxad simolenin + OBI-821 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC Recruiting
NCT03564782 Phase I PVSRIPO Examining Bioactivity of PVSRIPO in Invasive Breast Cancer Recruiting
NCT03567720 Phase II Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC Active, not recruiting
NCT03579472 Phase I Eribulin + M7824 M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03599453 Phase I Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03639948 Phase II Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) Recruiting
NCT03644589 Phase II Cisplatin + Pembrolizumab Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Withdrawn
NCT03654547 Phase I TT-00420 Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03674827 Phase I PF-06936308 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated
NCT03709446 Phase Ib/II Leflunomide Leflunomide in Previously Treated Metastatic Triple Negative Cancers Recruiting
NCT03719326 Phase I AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Recruiting
NCT03733119 Phase II ONC201 ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03742102 Phase Ib/II Durvalumab + Oleclumab + Paclitaxel Durvalumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) Recruiting
NCT03742349 Phase I Canakinumab + LAG525 + Spartalizumab LAG525 + MCS110 + Spartalizumab Capmatinib + LAG525 + Spartalizumab LAG525 + PBF-509 + Spartalizumab Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). Recruiting
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03800836 Phase I Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Recruiting
NCT03801369 Phase II Durvalumab + Olaparib Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03812393 Phase II Carboplatin + Neratinib + Paclitaxel Neratinib Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) Recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03838367 Phase Ib/II Carboplatin + Leronlimab Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03853707 Phase Ib/II Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Atezolizumab + Capecitabine + Ipatasertib Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Active, not recruiting
NCT03872388 Phase II Atorvastatin + Capecitabine Capecitabine Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Recruiting
NCT03872505 Phase II Carboplatin + Durvalumab + Paclitaxel Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) Not yet recruiting
NCT03875313 Phase Ib/II Talazoparib + Telaglenastat Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Recruiting
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Recruiting
NCT03893955 Phase I ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 ABBV-181 + ABBV-927 + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03901469 Phase II Talazoparib + ZEN-3694 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) Recruiting
NCT03911453 Phase I Rucaparib Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors Recruiting
NCT03911973 Phase Ib/II Gedatolisib + Talazoparib Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Recruiting
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting
NCT03941730 Phase II Estradiol Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Recruiting
NCT03945721 Phase I Niraparib A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients Recruiting
NCT03950570 Phase I ORIN1001 + Paclitaxel ORIN1001 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Recruiting
NCT03952325 Phase II Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) Recruiting
NCT03961698 Phase II Atezolizumab + Bevacizumab + IPI-549 Atezolizumab + IPI-549 + Nab-paclitaxel Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) Recruiting
NCT03971409 Phase II Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) Recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting
NCT03979508 Phase II Abemaciclib Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Recruiting
NCT03990896 Phase II Talazoparib Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Recruiting
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Recruiting
NCT03997123 Phase III Paclitaxel Capivasertib + Paclitaxel Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) Recruiting
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting
NCT04024436 Phase II Fulvestrant + Futibatinib Futibatinib A Study of TAS-120 in Patients With Metastatic Breast Cancer Recruiting
NCT04024800 Phase II AE37 + Pembrolizumab Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) Recruiting
NCT04032080 Phase II Prexasertib LY3023414 Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) Recruiting
NCT04039230 Phase Ib/II Sacituzumab govitecan-hziy + Talazoparib Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Recruiting
NCT04041128 Phase I Olaparib PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer Recruiting
NCT04052555 Phase I Berzosertib Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Recruiting
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04081389 Phase I Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Recruiting
NCT04095689 Phase II Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer Not yet recruiting
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT04111510 Phase II LN-145 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Recruiting
NCT04115306 Phase I PMD-026 Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer Recruiting
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting
NCT04176848 Phase II CFI-400945 + Durvalumab CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer Recruiting
NCT04177108 Phase III Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. Recruiting
NCT04185311 Phase I Ipilimumab + Nivolumab + Talimogene laherparepvec Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Recruiting
NCT04191135 Phase II Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Olaparib + Pembrolizumab Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Recruiting
NCT04216472 Phase II Alpelisib + Nab-paclitaxel Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations Recruiting
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting
NCT04230109 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan In TNBC (NeoSTAR) Recruiting
NCT04243616 Phase II Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer Recruiting
NCT04249167 Phase I Atezolizumab + Nab-paclitaxel Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting
NCT04265872 Phase I Bortezomib + Cisplatin + Pembrolizumab Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC Not yet recruiting
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR) Recruiting
NCT04331067 Phase Ib/II Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer Not yet recruiting
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) Recruiting
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting
NCT04348747 Phase II Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Not yet recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting
NCT04434040 Phase II Atezolizumab + Ipatasertib Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC Recruiting
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Not yet recruiting
NCT04443348 Phase II Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Pre-op Pembro + Radiation Therapy in Breast Cancer Not yet recruiting
NCT04445844 Phase II Pelareorep + Retifanlimab INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Recruiting
NCT04454528 Phase Ib/II Pembrolizumab BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Not yet recruiting
NCT04468061 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Recruiting
NCT04489940 Phase II M7824 Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer Not yet recruiting
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Recruiting
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Not yet recruiting